Veeva: Company Details, Growth, & Culture

This video explores Veeva Systems' role as the "operating system for Life Sciences," detailing its company structure, growth, and culture through an interview with Steve Harper, SVP Product Management. Veeva, founded in 2007 and serving 47 of the top 50 pharmaceutical companies, offers a combination of software, implementation services, and data services. The discussion highlights Veeva's dual focus on the commercial side of pharma and extensive work in research and development, including drug development, quality processes, clinical trials, and regulatory compliance. A key cultural aspect is their "two in the box" model, pairing technology experts with industry experts to build highly specific and effective products. The video also delves into Veeva's "Digital Trials Platform," aiming to make clinical trials 25% faster and cheaper by 2025 through digitization, and showcases Boehringer Ingelheim as a customer leveraging Veeva's integrated platform across their development process for significant savings and reduced complexity. Veeva's substantial growth, flexible work environment, and recent transition to a Public Benefit Corporation (PBC) status, emphasizing mission-driven work beyond profit, are also discussed as factors attracting talent and customers.

Key Takeaways:

• Veeva as the Life Sciences Operating System: Veeva positions itself as the foundational software platform for the life sciences industry, serving nearly all major pharmaceutical companies with a comprehensive suite of software, services, and data solutions across both commercial and R&D operations.
• Strategic "Two in the Box" Model: Veeva's core product development and cultural strategy involves pairing technology experts with industry experts.
• Focus on Clinical Trial Digitization: A major initiative is the "Digital Trials Platform," designed to significantly enhance the efficiency and cost-effectiveness of clinical trials by removing paper-based processes and improving data flow between all participants, aiming for a 25% improvement in speed and cost by 2025.
• Integrated Platform Adoption: Customers like Boehringer Ingelheim are adopting an "all-in" strategy with Veeva, using its integrated products across their entire development process (clinical, regulatory, quality). This demonstrates the value of a unified platform for reducing complexity and automating data flowai to assist clients with integration and optimization.
• Stability and Mission-Driven Growth: Veeva exhibits strong growth and stability within the life sciences sector, contrasting with broader tech industry slowdowns. Its conversion to a Public Benefit Corporation (PBC) underscores a commitment to employees, customers, and the community, aligning with a growing industry demand for ethical and impactful technology solutions.